HomeTagsBioMarin

BioMarin

Biotechnology

BioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO

PR Newswire - June 15, 2022

BioMarin Pharmaceutical Inc. presented data at The Endocrine Society Annual Meeting, ENDO 2022, demonstrating the Company's ongoing commitment to understanding the lifetime impact of...

Biotechnology

BioMarin Announces Oral Presentation of 2-Year Analysis of Largest Phase 3 Gene Therapy Study in Adults

PR Newswire - February 7, 2022

BioMarin Pharmaceutical Inc. announced that the Company presented positive results from a two-year analysis of the Phase 3 GENEr8-1 study and an overall safety...

Biotechnology

BioMarin Demonstrates Enduring Commitment to Advancing the Standard of Care in Hemophilia A

PR Newswire - February 3, 2022

BioMarin Pharmaceutical Inc. announced that the Company will be presenting data in several presentations on valoctocogene roxaparvovec, an investigational gene therapy for the treatment...